Researchers and company officers at Mannatech did not return repeated calls from the Chronicle. We enlisted the help of a local marketer for the company, but we were still unable to reach a spokesperson or researcher associated with the firm. A secretary said the company’s researchers do not give media interviews, would have nothing to add to the published results of their studies, and would not comment on a specific trial until the results were published.
The company, based in Coppell, Texas, sells a variety of nutritional supplements based on Ambrotose through a network marketing system. Its published material describes Ambrotose as a carbohydrate complex containing eight essential sugars. The company’s literature claims the products improve cellular communication, help the body burn fat and regenerate skin tissue, aid in energy production and in the recovery from physical or emotional stress, and support the immune system. Other materials published or distributed by the company suggest that its products can be helpful in treating alcoholism, dyslexia, hepatitis C, herpes infections, periodontal disease, asthma and Tay-Sachs disease, in addition to chronic fatigue syndrome.
The study at the New Jersey CFS Research Center is believed to be the first independent trial of the product for CFS.